nivolumab + BMS-813160

Combination of **nivolumab** (a human IgG4 monoclonal antibody that inhibits the immune checkpoint programmed death-1 receptor (PD-1), enhancing T cell anti-tumor activity) and **BMS-813160** (an investigational oral small molecule dual antagonist targeting C-C chemokine receptor 2 (CCR2) and C-C chemokine receptor 5 (CCR5) on monocytes/macrophages and certain tumor cells). This combination is being investigated primarily in advanced solid tumors, especially metastatic colorectal and pancreatic cancers, for synergistic immunomodulation—nivolumab re-activates T cell immunity, while BMS-813160 limits immunosuppressive cell infiltration into tumors and may inhibit tumor growth, angiogenesis, and metastasis[2][3][4][6][8].

Brand names

Opdivo

Other names

N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo(1,5-a)(l,3,5)triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide